SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation

SPARC Enters into a Licensing Deal with CMS

SPARC to Provide Update on R&D Pipeline

SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia

SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension

Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

Audio playback of Investors Presentation